Autolus Therapeutics Plc (AUTL) has released an update to notify the public and investors about an entry into a material definitive agreement.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Autolus Therapeutics plc has entered into an underwriting agreement with Jefferies LLC and Truist Securities, Inc., launching a registered direct offering of 58.3 million American Depositary Shares at $6.00 each, aiming to raise $350 million. The offering, detailed in a recent SEC filing, is set to close around February 12, 2024, with standard closing conditions. This significant financial move, underpinned by customary legal agreements, indicates a robust step for the company in securing its financial future.
For further insights into AUTL stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.